Physician profile
Angela Kaplan
NPI 1538260906
$5,607.06
in general payments reported to CMS, 2019-2025
23 companies · $1,096 in 2025
The $1,096 reported for 2025 was more than what 92% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,157 · 2020: $410 · 2021: $905 · 2022: $698 · 2023: $610 · 2024: $730 · 2025: $1,096.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,320 · Entertainment: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,320.36 |
| Entertainment | $116.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $579.61 | 2019-2025 | Myday Contact Lens, Misight Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $519.37 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $496.22 | 2022-2024 | Infuse, Infuse Multifocal |
| Biotissue Holdings INC. | $456.33 | 2024-2025 | |
| Optos, INC. | $428.86 | 2019-2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Alcon Vision LLC | $371.14 | 2021-2025 | Tryptyr |
| Sun Pharmaceutical Industries INC. | $358.73 | 2019-2022 | |
| Allergan, INC. | $356.10 | 2019-2021 | |
| Glaukos Corporation | $264.91 | 2019-2025 | Idosetr |
| Dompe US, INC. | $246.41 | 2021-2024 | Oxervate |
| Abbvie INC. | $242.74 | 2022-2025 | |
| Ocular Therapeutix, INC. | $237.36 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $181.31 | 2019-2021 | |
| Optovue, INC. | $178.39 | 2019-2021 | |
| Sight Sciences, INC. | $100.38 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $100.00 | 2025 | Acuvue |
| Tarsus Pharmaceuticals, INC. | $99.93 | 2025 | Xdemvy |
| Oyster Point Pharma, INC. | $98.08 | 2023-2024 | Tyrvaya |
| Lkc Technologies, INC. | $88.46 | 2025 | |
| Amgen INC. | $84.48 | 2024 | Tepezza |
| Novartis Pharmaceuticals Corporation | $43.79 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $39.27 | 2019 | |
| Visionix USA, INC | $35.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Kaplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.